Therapy of localized gastric cancer: Preoperative and postoperative approaches

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 7-12

  Yao, J C ^a   Ajani, J A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; LOMUSTINE; METHOTREXATE; MITOMYCIN; MITOMYCIN C; PICIBANIL; PLATINUM; TEGAFUR; THIOTEPA; URACIL; VINCRISTINE;

ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FOOD FREEZING; FOOD PRESERVATION; GASTRECTOMY; GASTROESOPHAGEAL REFLUX; HIGH RISK PATIENT; OBESITY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; SURVIVAL RATE;

EID: 0036434648     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf632     Document Type: Article

References (63)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Vaughan TL, Davis S, Kristal A et al. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: Adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92.
3. Chow WH, Blot WJ, Vaughan TL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150-155.
4. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130:883-890.
5. Siewert JR, Bottcher K, Stein HJ et al. Relevant prognostic factors in gastric cancer: 10-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.
6. Kim JP, Lee JH, Kim SJ et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998; 1: 125-133.
7. Yao JC, Chiang S, Yu C et al. The effects of gender and ethnicity on gastric cancers localization. Proc Am Soc Clin Oncol 2001; 20: 165a (Abstr 658).
8. Kuwahara A, Katano M, Nakamura M et al. New therapeutic strategy for gastric carcinoma: a two-step evaluation of malignant potential from its molecular biologic and pathologic characteristics. J Surg Oncol 1999; 72: 142-149.
9. Katano M, Nakamura M, Fujimoto K et al. Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 1998; 227: 365-371.
10. Jaehne J, Urmacher C, Thaler HT et al. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 474-479.
11. Albino AP, Jaehne J, Altorki N et al. Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. Eur J Surg Oncol 1995; 21: 56-60.
12. Lee EY, Cibull ML, Strodel WE et al. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 1994; 118: 235-239.
13. Metzger R, Danenberg K, Danenberg P et al. Excision repair cross complementing (ERCC)-1 gene in primary gastric cancer: a determinant of response to cisplatin-based chemotherapy. Proc Am Soc Clin Oncol 1996; 15: 505a.
14. Metzger R, Danenberg K, Hayashi K et al. ERCC1 expression correlates with response of primary gastric cancer to cisplatin-based chemotherapy (Meeting abstract) Proc Ann Meet Am Assoc Cancer Res 1996; 37: A1350.
15. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316.
16. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 2000; 88: 921-932.
17. Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Huntingt) 1999; 13: 1485-1494; discussion 1497-1502.
18. Schiessel R, Funovics J, Schick B et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial. Acta Medica Austriaca 1989; 16: 68-69.
19. Sautner T, Hofbauer F, Depisch D et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974.
20. Hagiwara A, Takahashi T, Kojima O et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629-631.
21. Rosen HR, Jatzko G, Repse S et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16: 2733-2738.
22. Yu W, Whang I, Suh I et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-354.
23. The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988; 75:1100-1104.
24. Kim JP, Kwon OJ, Oh ST et al. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992; 216: 269-278; discussion 278-269.
25. Jakesz R, Dittrich C, Funovics J et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 1988; 110: 44-51.
26. Dent DM, Werner ID, Novis B et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979; 44: 385-391.
27. Gunderson LL, Hoskins RB, Cohen AC et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 1983; 9: 965-975.
28. Gez E, Sulkes A, Yablonsky-Peretz T et al. Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma. J Surg Oncol 1986; 31: 139-142.
29. Gez E, Sulkes A, Peretz T et al. Combined 5-fluorouracil and radiation therapy following resection of locally advanced gastric carcinoma: a 5-year follow-up. Recent Results Cancer Res 1988; 110: 52-56.
30. Moertel CG, Childs DS, O'Fallon JR et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984; 2: 1249-1254.
31. Bleiberg H, Goffin JC, Dalesio O et al. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol 1989; 15: 535-543.
32. Regine WF, Mohiuddin M. Impact of adjuvant therapy on locally advanced adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 992; 24: 921-927.
33. Henning GT, Schild SE, Stafford SL et al. Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 589-598.
34. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
35. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
36. Lowy AM, Feig BW, Janjan N et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8: 519-524.
37. Veterans Administration Surgical Oncology Study Group. Use of thio-TEPA as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1965; 18: 291-297.
38. Carrato A, Diaz-Rubio E, Medrano J et al. Phase III trial of surgery versus adjuvant chemotherapy with mitomycin C (MMC) and tegafur plus uracil (UFT), starting within the first week after surgery, for gastric adenocarcinoma. Proc Am Soc Clin Oncol 1995; 14: 468a.
39. Longmire WP Jr, Kuzma JW, Dixon WJ. The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann Surg 1968; 167: 293-312.
40. Nakajima T, Nashimoto A, Kitamura M et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Lancet 1999; 354: 273-277.
41. Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977; 2: 213-221.
42. Higgins GA Jr, Amadeo JH, McElhinney J et al. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report. Cancer 1984; 53: 1-8.
43. Engstrom PF, Lavin PT, Douglass HO Jr et al. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985; 55: 1868-1873.
44. Yu W, Whang I, Averbach A et al. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. American Surgeon 1998; 64: 1104-1108.
45. Macdonald JS, Fleming TR, Peterson RF et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494.
46. Lise M, Nitti D, Marchet A et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763.
47. Coombes RC, Schein PS, Chilvers CE et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990; 8: 1362-1369.
48. Hallissey MT, Dunn JA, Ward LC et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312.
49. Krook JE, O'Connell MJ, Wieand HS et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458.
50. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. Five-year follow-up of first British Stomach Cancer Group trial. Lancet 1989; 1: 571-574.
51. Grau JJ, Estape J, Alcobendas F et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993; 29A: 340-342.
52. The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116-1122.
53. Neri B, de Leonardis V, Romano S et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996; 73: 549-552.
54. Grau JJ, Estape J, Fuster J et al. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998; 16: 1036-1039.
55. Cirera L, Balil A, Batiste-Alentorn E et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815.
56. Ajani JA, Ota DM, Jessup JM et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68: 1501-1506.
57. Ajani JA, Mayer RJ, Ota DM et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993; 85: 1839-1844.
58. Fink U, Schuhmacher C, Stein HJ et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248-1252.
59. Rougier P, Mahjoubi M, Lasser P et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A: 1269-1275.
60. Crookes P, Leichman CG, Leichman L et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 1997; 79: 1767-1775.
61. Kelsen D, Karpeh M, Schwartz G et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1818-1828.
62. Yonemura Y, Sawa T, Kinoshita K et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993; 17: 256-261.
63. Ajani JA, Mansfield PF, Lynch PM et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999; 17: 2403-2411.